Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer —from Promise to Reality

AbstractPurpose of ReviewPrecision medicine and personalized treatment recommendations have become standard for systemic therapy decision-making in women with breast cancer. Until recently, however, such opportunities have been lacking for radiation related treatment decisions.Recent FindingsRecent studies have explored the utility of using genomic signatures developed to make systemic therapy recommendations (e.g. Oncotype DX ®, ProSigna®, IHC4-C) to guide recommendations for radiation as well. Emerging data suggests that these signatures, while prognostic, may not identify radiation benefit. Radiation-specific signatures are currently under clinical development and may soon be ready for clinical implementation. These classifiers may better be able to determine radiation benefit and detect cancers with intrinsic radiation resistance.SummaryWe are beginning to realize the promise of precision medicine for radiation treatment decisions in women with breast cancer. Previously developed genomic signatures are currently being tested for radiation-related questions, and radiation-specific signatures and radiation toxicity biomarkers are moving into clinical implementation. These advances make clear that genomic classifiers show more than mere promise and will soon allow for personalized radiation recommendations.

Source: Current Breast Cancer Reports - October 3, 2020 Category: Cancer & Oncology Source Type: research